Europe’s structural heart occlusion devices market is expected to grow steadily, driven by rising prevalence of atrial fibrillation (AF), greater stroke-risk awareness, and wider adoption of minimally invasive left atrial appendage (LAA) occlusion procedures. Increasing physician experience with transcatheter procedures and improvements in device design are also expected to expand patient eligibility. Amid these trends, Europe’s structural heart occlusion devices market is projected to grow at a compound annual growth rate (CAGR) of approximately 6% through 2036, according to GlobalData, leading intelligence and productivity platform.

GlobalData’s latest report, “Structural Heart Occlusion Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that Europe accounted for nearly 20% of the global structural heart occlusion devices market in 2025, with LAA closure devices driving the regional market at 63% of Europe’s total structural heart occlusion devices market.

Aakansha Pankaj, Medical Devices Analyst at GlobalData, comments: “Europe’s structural heart occlusion devices market is benefiting from the growing clinical acceptance of LAA closure as an important stroke-prevention strategy for selected patients with atrial fibrillation. Improvements in device conformability, sealing performance, and procedural ease are helping physicians address a broader range of LAA anatomies, while increasing clinical experience is supporting broader adoption of transcatheter occlusion technologies.

Within Europe’s evolving structural heart landscape, Abbott’s Amulet 360 LAA Occluder receiving CE Mark represents a notable next-generation update in stroke prevention for patients with non-valvular atrial fibrillation. The next-generation device features a redesigned, more conformable lobe and dual-seal design intended to accommodate different LAA anatomies. The device has already been used in initial European cases in Germany and Denmark, with Abbott planning broader expansion across European countries.

Pankaj concludes: “While the high cost of structural heart occlusion procedures, limited access to specialized centers, and the need for experienced interventional teams remain barriers to broader adoption, continued improvements in device design and clinical confidence are expected to expand the use of LAA closure. Growing demand for minimally invasive stroke-prevention options will support long-term market growth across Europe.”